TCET (Transitional Coverage for Emerging Technologies)

TCET (Transitional Coverage for Emerging Technologies) is a Medicare coverage pathway the Centers for Medicare & Medicaid Services (CMS) finalized in August 2024 to close a specific gap: an FDA-designated Breakthrough Device could reach the U.S. market with FDA authorization in hand and still wait a year or more for a Medicare national coverage decision, because the standard National Coverage Determination (NCD) process was never designed to start before a product existed. TCET does not create a new coverage authority — it re-sequences CMS’s existing NCD and Coverage with Evidence Development (CED) tools so the evidence-gathering and coverage-drafting work happens in parallel with FDA’s own review, instead of only starting after market authorization.

Eligibility: What Makes a Device TCET-Eligible

CMS finalized a narrow eligibility test. A device qualifies for TCET only if it meets all of the following:

• It holds an active FDA Breakthrough Device designation (reserved for devices offering more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions).
• It has received FDA market authorization (clearance, de novo classification, or approval).
• It falls within an existing Medicare benefit category — TCET does not create new benefit categories, so a genuinely novel item type that Medicare has no statutory basis to pay for at all is out of scope regardless of its Breakthrough status.
• It is not already the subject of an existing NCD.

CMS also finalized an explicit exclusion for digital-only technologies from TCET eligibility, and capped the pathway at five new candidates accepted per year, with applications reviewed on a quarterly cycle — a nomination that misses the cap in one quarter rolls automatically into the next rather than requiring resubmission.

The TCET Process, Step by Step

TCET is built around engaging CMS well before a device reaches the market, on a timeline manufacturers need to plan around from early in the FDA review process:

1. Letter of Intent — a non-binding notice to CMS roughly 18-24 months before anticipated FDA authorization.
2. Self-nomination — a formal nomination submitted roughly 12 months before anticipated authorization.
3. Evidence preview — a CMS-contractor-generated assessment of the clinical-evidence gaps standing between the existing data and a favorable national coverage decision.
4. Evidence Development Plan (EDP) — the manufacturer’s roadmap, built against the evidence preview, for the additional data CMS will need.
5. Coverage decision — once FDA authorizes the device, CMS opens an NCD conditioned on CED, with evidence summaries posted for public comment as part of the standard NCD process.

Coverage Duration

A device that completes the TCET pathway receives national Medicare coverage — not the patchwork of contractor-level coverage decisions a new device would otherwise have to accumulate MAC by MAC — for a defined period while the manufacturer executes its Evidence Development Plan. Secondary reporting on the final notice describes this window as running several years, potentially up to roughly five, after which CMS reconsiders coverage in light of the evidence collected.

How TCET Relates to CED, NCD 310.1, Category A/B IDE Payment, and RAPID

TCET sits in a cluster of Medicare device-coverage mechanisms that are easy to conflate but answer different questions:

• Coverage with Evidence Development (CED) is the general CMS mechanism — used within many NCDs, not only TCET ones — that conditions coverage on a patient’s care contributing data to a registry or study. TCET does not replace CED; it is a structured, pre-planned way of arriving at a CED-conditioned NCD faster for a narrow slice of Breakthrough Devices.
• NCD 310.1 answers a different question entirely: whether Medicare covers the routine patient-care costs of a beneficiary enrolled in a qualifying clinical trial. It has nothing to do with device-specific coverage decisions.
• The Category A/B Investigational Device Exemption (IDE) payment framework (42 CFR 405.201-405.215) governs Medicare payment for devices still under an active FDA investigational study, before market authorization — a pre-market question, whereas TCET only applies after FDA authorization.
• The newer RAPID Coverage Pathway, which CMS and FDA jointly announced in April 2026, targets an even faster on-ramp — a proposed NCD the same day as FDA authorization — for a subset of Breakthrough Devices meeting additional criteria. Reported industry coverage of the RAPID announcement describes CMS as pausing new TCET candidate intake while RAPID is stood up, without displacing devices already inside the TCET pathway; treat this transition as an evolving, time-sensitive process detail rather than a settled fact, and verify current intake status against CMS’s own TCET and RAPID pages before relying on it.

Why This Matters for Research Administrators and Clinical Operations Teams

For sites and sponsors running post-authorization studies tied to a device’s Evidence Development Plan, TCET’s timeline has direct billing and study-design consequences: national coverage is not automatic or indefinite, it is conditioned on the study CMS and the manufacturer agreed to, and a site’s research billing office needs to know whether a given device’s Medicare claims are being paid under a TCET-linked CED study versus under a separate, unrelated coverage decision. Confirming which pathway — TCET, standalone CED, Category A/B IDE payment, or the newer RAPID track — actually governs a given device is a necessary first step before assuming Medicare will pay for a study participant’s related care.